An odd but synergistic couple: Immunotherapy combined with radiotherapy

In summary, there is considerable promise for combinations of immunotherapy with radiotherapy, but clinical experience is still limited. Preclinical models with greater relevance to human tumors should be used to continue identifying the best combinations and timing of radiation therapy and immunotherapy, but of course, only clinical trials will establish the true value of these combinations. Because we are entering an era with numerous therapies for cancer, all of which might act synergistically, the importance of patient selection is paramount. Predictive factors that indicate which patients are most likely to benefit from immunotherapy or radiation therapy are critically needed.

Duke Scholars

Author Michael Aaron Morse Medicine, Medical Oncology

Author Christopher G. Willett Radiation Oncology